T1	Participants 75 103	recurrent gastric carcinoma.
T2	Participants 232 247	cancer patients
T3	Participants 369 418	a group of patients with recurrent gastric cancer
T4	Participants 482 569	1) Intradermal group (ID Group), 42 patients given an intradermal injections of OK-432.
T5	Participants 570 661	2) Intramuscular group (IM Group), 40 patients given an intramuscular injections of OK-432.
T6	Participants 662 723	3) Control group (C Group), 39 patients not given injections.
